HUTCHMED's Savolitinib Combined with Tagrisso Achieves Primary OS Endpoint in Phase III Trial
nashnova research
Hutchmed announced that SAFFRON, its global phase III trial, met the primary overall-survival endpoint — savolitinib plus osimertinib extended median survival by nearly 5 months in advanced lung cancer patients who had progressed on osimertinib, marking the first all-oral targeted regimen to show an OS benefit after osimertinib resistance and opening a direct path to global regulatory filings.
What problem is this trial trying to solve?
About one-third of EGFR-mutant non-small-cell lung cancer patients develop resistance to Tagrisso (osimertinib) driven by MET abnormalities — MET overexpression or amplification, essentially an "escape route" the tumour uses to reactivate growth signals around the drug's blockade.
After resistance, the current standard of care is platinum-based doublet chemotherapy — limited efficacy, significant side effects, and no precision oral option targeting the MET mechanism.
This means → SAFFRON aimed squarely at this clinical gap: can an oral targeted combination replace chemotherapy and extend survival?
How strong is the efficacy data?
Progression-free survival (PFS): median 7.6 months in the combination arm vs 5.4 months with chemotherapy — a 45% reduction in the risk of progression or death (HR 0.55, p<0.001); 1-year progression-free rates 36% vs 10%.
Overall survival (OS): median 17.8 months vs 12.9 months — a 32% reduction in the risk of death (HR 0.68, p=0.010), extending median survival by 4.9 months; 1-year survival rates 70% vs 53%.
In plain terms = "dual-endpoint positivity" on both PFS and OS is the gold standard in oncology trials — it shows the regimen not only slowed the disease but genuinely helped patients live longer, which is the evidence regulators value most when approving a drug.
Where were the data presented, and how significant is that?
Results were presented at the 2026 ESMO Annual Meeting Presidential Symposium (abstract #LBA6) and simultaneously published in The New England Journal of Medicine.
This means → the ESMO Presidential Symposium is reserved for the year's highest-impact clinical data; concurrent NEJM publication adds the top-tier academic endorsement in oncology, paving the way for global regulatory submissions.
What are key stakeholders saying?
Global principal investigator Prof. Lu Shun of Shanghai Chest Hospital said the regimen "has the potential to set a new clinical benchmark" and stressed the urgent need for MET testing to guide treatment.
Hutchmed acting CEO Eddy Zheng called the data "a decisive step in addressing MET-driven resistance," offering patients "a meaningful all-oral treatment option."
AstraZeneca oncology R&D head Susan Galbraith said the combination "could become the first biomarker-directed, all-oral option in this setting."
What does this mean for Hutchmed?
Savolitinib is Hutchmed's proprietary MET inhibitor — a targeted drug designed to block the MET signalling pathway. Achieving positive phase III results in combination with AstraZeneca's osimertinib represents a milestone-grade readout for Hutchmed's pipeline.
This means → the next critical catalyst is the pace of global regulatory filings and approvals — converting phase III data into a new indication will directly determine how the market re-prices Hutchmed's pipeline value.
This reflects a broader trend: in the era of precision oncology, "what to do after resistance" is becoming one of the most commercially valuable R&D directions for pharma companies.
市场有风险，内容仅供研究参考，不构成投资建议。